Cancer patients harboring specific KRAS mutations have long faced limited treatment options, representing one of oncology's most challenging therapeutic gaps. The KRAS G12D variant drives roughly 5% of lung cancers and 40% of pancreatic cancers, yet until now has remained largely "undruggable" despite decades of research efforts.
This phase 1 trial of setidegrasib, a novel protein degrader targeting KRAS G12D specifically, enrolled 203 patients with advanced solid tumors. At the optimal 600mg weekly intravenous dose, 36% of lung cancer patients achieved partial responses, with manageable side effects primarily consisting of infusion reactions and nausea. The mechanism represents a departure from traditional kinase inhibition, instead employing targeted protein degradation to eliminate the mutant KRAS protein entirely.
This approach addresses a fundamental challenge in precision oncology. Previous KRAS inhibitors have struggled with resistance and limited efficacy, particularly against the G12D variant which lacks the reactive cysteine residue that enables covalent binding of existing drugs like sotorasib. Protein degraders offer theoretical advantages through sustained target elimination rather than reversible inhibition, potentially overcoming resistance mechanisms that plague conventional approaches.
While promising, these results require contextual interpretation. The 36% response rate in heavily pretreated lung cancer patients exceeds typical expectations for late-line therapy, yet durability data and comparison to standard care remain incomplete. The infusion-related reactions, while manageable, may limit broader applicability. Most critically, pancreatic cancer responses appear more modest, suggesting tissue-specific factors may influence efficacy. This represents meaningful progress toward addressing KRAS G12D, though clinical benefit will ultimately depend on response durability and optimal patient selection strategies.